Johnson & Johnson (JNJ) EPS (Weighted Average and Diluted) (2009 - 2026)

Johnson & Johnson has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $2.14 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $2.14, down 52.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.64 (down 3.89% YoY), and the FY2025 annual result was $11.03, up 90.5% from the prior year.
• EPS (Weighted Average and Diluted) came in at $2.14 for Q1 2026 at Johnson & Johnson, up from $2.09 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $10.21 in Q4 2023 to a low of -$0.09 in Q3 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is $1.8 (2022), against an average of $2.2.
• Across the five-year window, EPS (Weighted Average and Diluted) slumped 104.9% in 2023 and surged 4566.67% in 2024, its largest moves.
• Johnson & Johnson's EPS (Weighted Average and Diluted) stood at $1.68 in 2022, then advanced by 1.19% to $1.7 in 2023, then decreased by 17.06% to $1.41 in 2024, then soared by 48.23% to $2.09 in 2025, then rose by 2.39% to $2.14 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $2.14 (Q1 2026), $2.09 (Q4 2025), and $2.12 (Q3 2025), per Business Quant data.